Four Bipolar Cases Treated with Quetiapine During Pregnancy


DEGERLI H. E., Altinbas K., DEUCE M., KURT E.

KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, cilt.24, sa.4, ss.391-395, 2014 (SCI-Expanded) identifier identifier

Özet

Bipolar disorder is a disease that typically begins in adolescence and early adulthood, namely during the reproductive period. The treatment of female cases during their reproductive years is very important because of the teratogenic effects of psychotropic drugs. It has been stated that the use of classical antipsychotics during pregnancy was not associated with congenital malformations or low birth weight. While all drugs pass through the placenta, quetiapine shows the lowest degree of placenta transit of all the antipsychotics. Studies with animals have not showed any teratogenic effect. Even though studies with humans are very limited with respect to embryonic/fetal risk assessment, recent studies have shown no increased risk of birth defects in quetiapine exposed babies and when compared to other treatment alternatives, quetiapine can be used safely in pregnancy. In this article, we report that no negative data has been found in terms of teratogenicity or perinatal complications in the cases of four pregnant women being treated with quetiapine in the manic and depressive episodes of bipolar disorder and it is also reported that quetiapine can reliably be used during pregnancy.